This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Ultimately, the study found that patient AIRE scores accurately predicted CV death (HR: 2.24), HF risk (HR: 2.60), MI (HR: 3.13), ischemic stroke (HR: 1.23), and CKD (HR: 1.89) compared to traditional risk factors. AIRE-HTN was trained on ~190k patients at Beth Israel Deaconess and validated on 65k patients from UK Biobank.
Stroke, Volume 56, Issue Suppl_1 , Page ANS8-ANS8, February 1, 2025. Background and Purpose:Patients discharged home after a stroke are particularly vulnerable during the immediate post-discharge period. Patients were seen by the outpatient stroke NP within 7 to 14 days, either in clinic or via telemedicine.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP82-AWMP82, February 1, 2025. Our Comprehensive Stroke Center identified critical gaps in post-discharge care, including inconsistent follow-up timing and a high rate of missed appointments.
The CardiAMP HF trial is supported by the Maryland Stem Cell Research Fund and has reimbursement from the Centers for Medicare and Medicaid Services (CMS) for both treatment and control procedures. The CardiAMP HF II trial is expected to similarly secure CMSreimbursement. vs. 13.2%, respectively).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content